Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Canadian Ticagrelor Survey

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 18, 2012
Last updated: December 8, 2015
Last verified: December 2015
This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Acute Coronary Syndrome

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue) [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • KAU Questionnaire: Practice characteristics [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns. [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Enrollment: 244
Study Start Date: November 2012
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

Detailed Description:
Effectiveness of risk minimisation interventions for ticagrelor in Canada

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All physicians who have prescribed at least one dose of ticargrelor and complete the Knowledge and understanding survey

Inclusion Criteria:

- N/A (All prescribers will be contacted for participation)

Exclusion Criteria:

- Participation in a previous wave of the survey.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01757483

Canada, Quebec
Research Site
Montreal, Quebec, Canada
Sponsors and Collaborators
Principal Investigator: Yola Moride, PhD Université de Montréal
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT01757483     History of Changes
Other Study ID Numbers: D5130L00009 
Study First Received: December 18, 2012
Last Updated: December 8, 2015
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on October 25, 2016